title: [Clinical efficacy of treating infant cytomegalovirus hepatitis with ganciclovir and impact on cytokines].
abstract: OBJECTIVE
  To observe the clinical efficacy of treating infant cytomegalovirus (CMV) hepatitis with ganciclovir and impact on cytokines.
  
  
  METHODS
  76 patients with CMV hepatitis infant were randomly divided into treatment group and control group. The patients of two groups were treated using conventional therapy, on the basis of conventional therapy the treatment group was treated using induction and maintenance treatment of ganciclovir. Before and after treatment the growth and decline in jaundice, liver function, side effects and IL-8 and IFN-γ levels of the patients were detected, clinical efficacy was evaluated.
  
  
  RESULTS
  The clinical total effective rate of the treatment group was 91.4%, it was significantly higher than that of the control group (71.4%), compared with the control group the difference was significant (P < 0.05). After treatment, the growth and decline of jaundice (TBIL and DBIL), liver enzymes (ALT and AST) and cytokines (IL-8 and IFN-γ) levels increased, compared with the pre-treatment and the control group the difference was significant (P < 0.05). The treatment group was no adverse reaction.
  
  
  CONCLUSIONS
  The induction and maintenance treatment of ganciclovir in treatment of infant CMV hepatitis can make the body to restore balance of specific cellular immunity, and can significantly improve the symptoms of jaundice, liver function and clinical efficay and it is worthy to be popularized.
authors.affiliation: Department of Infections and Digestive, Children's Hospital of Chongqing Medical University, Chongqing, China. xiongwan1962@yahoo.com.cn
authors.forename: Wan
authors.initials: W
authors.lastname: Xiong
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D016207:Cytokines / Q000097:blood*; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use*; D006525:Hepatitis, Viral, Human / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007223:Infant; D007371:Interferon-gamma / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D008297:Male
chemical_list: D000998:Antiviral Agents; D016207:Cytokines; D016209:Interleukin-8; D007371:Interferon-gamma; D015774:Ganciclovir